Insmed is a biopharmaceutical company focused on developing and commercializing inhalation therapies in orphan patient populations with critical unmet needs to improve the lives of patients battling serious orphan lung diseases. ARIKACE, the company’s lead candidate, is designed to deliver a proven and potent anti-infective directly to the site of serious lung infections. Top-line clinical results of the phase 3 registrational study of ARIKACE in Europe and Canada are expected in mid-2013. For more information, visit the company’s Web site: http://www.insmed.com

Let us hear your thoughts below: